|Bid||3.0500 x 900|
|Ask||3.0600 x 1300|
|Day's Range||2.9250 - 3.1150|
|52 Week Range||1.7000 - 4.0300|
|Beta (5Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Accuray (NASDAQ: ARAY) were up as much as 17.6% on Thursday. The medical instruments maker, which specializes in radiation oncology machines, released its fiscal 2023 second-quarter earnings report late Wednesday. In the second-quarter report, CEO Suzanne Winter said the company set a record with 29 new systems delivered.
Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.
Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?